Marcelo C Pasquini
Overview
Explore the profile of Marcelo C Pasquini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
4664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerjee R, Fritz A, Akhtar O, Freeman C, Cowan A, Shah N, et al.
Leukemia
. 2025 Feb;
PMID: 39994463
No abstract available.
2.
Locke F, Siddiqi T, Jacobson C, Nikiforow S, Ahmed S, Miklos D, et al.
Blood Adv
. 2025 Jan;
PMID: 39883946
Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR...
3.
Akhtar O, Oloyede T, Brazauskas R, Afrough A, Hashmi H, Sidana S, et al.
Blood Adv
. 2025 Jan;
PMID: 39786391
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of...
4.
Chung D, Shah N, Wu J, Logan B, Bisharat L, Callander N, et al.
Clin Cancer Res
. 2024 Oct;
30(19):4542.
PMID: 39350638
No abstract available.
5.
Wu J, Estrada-Merly N, Dhakal B, Mohan M, Narra R, Pasquini M, et al.
Transplant Cell Ther
. 2024 Sep;
30(12):1189.e1-1189.e10.
PMID: 39277111
Despite the use of autologous hematopoietic cell transplantation (AHCT) in treatment of multiple myeloma (MM) for almost 40 years and its persistence as standard of care in transplantation-eligible patients with...
6.
Greco R, Badoglio M, Labopin M, Kaur M, Pasquini M
Handb Clin Neurol
. 2024 Aug;
202():295-305.
PMID: 39111915
Hematopoietic stem cell transplantation (HSCT) has evolved over the last 25 years as a specific treatment of patients with severe neurologic autoimmune diseases (ADs), through eradication of the pathologic, immunologic...
7.
Baldomero H, Neumann D, Hamad N, Atsuta Y, Sureda A, Iida M, et al.
Best Pract Res Clin Haematol
. 2024 Aug;
37(2):101556.
PMID: 39098798
Hematopoietic cell transplantation (HCT) was developed more than 65 years ago to treat malignant blood disorders and irreversible bone marrow failures, with the aim of replacing a diseased hematopoietic system...
8.
Kean L, Burns L, Kou T, Kapikian R, Lozenski K, Langston A, et al.
Blood
. 2024 Jul;
144(17):1834-1845.
PMID: 39028876
Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first US Food and Drug Administration (FDA)-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT). Using Center for...
9.
Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):917.e1-917.e12.
PMID: 38944153
The Center for International Blood and Marrow Transplant Research (CIBMTR) prepares an annual set of summary slides to summarize the trends in transplantation and cellular therapies. For the first time...
10.
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos J, Iida M, et al.
Haematologica
. 2024 May;
109(10):3282-3294.
PMID: 38721749
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for...